The company’s weight loss therapy was able to sustain itself for up to 40 days in obese patients after a single injection.
Gilead presented the data at the Conference on Retroviruses and Opportunistic Infections (CROI 2025). Image credit: Shutterstock / Sundry Photography Gilead is set to launch a Phase III trial of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback